Views
4 years ago

13 - EM Ylarri - Julio de 2011

  • Text
  • Ylarri
  • Cardiovascular
  • Receptor
  • Angiotensina
  • Aumento
  • Angiotensina
  • Sraa
  • Cardiovascular
  • Angiotensin
  • Hipertrofia
  • Receptor
  • Ventricular
  • Efectos
  • Ieca
Efectos de la Inhibición del Sistema Renina-Angiotensina independientes del descenso de la presión arterial

Referencias

Referencias bibliográficas 1. Lewington S et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913. 2. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991;121:1244–63. 3. Appel GB and Appel AS. Angiotensin II Receptor Antagonists: Role in Hypertension, Cardiovascular Disease, and Renoprotection. Progress in Cardiovascular Diseases, 2004;47:105-115. 4. Vanderhevden PM From angiotensin IV binding site to AT4 receptor. Mol Cell Endocrinol. 2009;302:159-66. 5. Zulli A, Burrell LM, Buxton BF, Hare DL. ACE2 and AT4R are present in diseased human blood essels. Eur J Histochem. 2008;52:39-44. 6. Jorde UP. Suppression of the Renin–Angiotensin–Aldosterone System in Chronic Heart Failure Choice of Agents and Clinical Impact. Cardiology in Review 2006;14: 81–87. 7. Baldoncini R, Desideri G, Bellini C, et al. High plasma renin activity is combined with elevated urinary albumin excretion in essential hypertensive patients. Kidney Int 1999; 56:1499-504. 8. Weintrau HS, Tran H, and Schwartzbard A Potential Benefits of Aliskiren Beyond Blood Pressure Reduction Cardiology in Review 2011;19: 90–94. 9. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345: 1667–1675. 10. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM Added trial. Lancet. 2003;362:767–771. 11. Ylarri, EM and Lipszyc PS Tratamiento de la hipertensión arterial: de la patogenia a los efectos farmacológicos (Capítulo I): Bloqueantes del sistema nervioso simpático Farmacología Cardiovascular 2004;5:12-17. 12. Edwin K. Jackson. Diuretics. In Goodman and Gilman’s The Pharmacological Bases of Therapeutics. McGraw-Hill, New York, 2001. 13. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA 2001; 286:1882–1885. 14. The ALLHAT Officers and Coordinators for the ALL- HAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981–2997. 15. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint Reduction in Hypertension Study. J Hypertens 2002;20:1879–1886. 16. Chow L, De Gasparo M, Levens N. Improved glucose metabolism following blockade of angiotensin converting enzyme but not angiotensin AT1 receptors. Eur J Pharmacol 1995; 282:77–86. 17. Kurtz TW and Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin–angiotensin system. Journal of Hypertension 2004, 22:2253–2261. 18. Kudoh A, Matsuki A. Effects of angiotensin-converting enzyme inhibitors on glucose uptake. Hypertension 2000; 36:239–244. 19. Bernobich E, de Angelis L, Lerin C, Bellini G The role of the angiotensin system in cardiac glucose homeostasis: therapeutic implications. Drugs 2002; 62: 1295-314. 20. Fogari R, Zoppi A, Lazzari P, et al. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol 1998; 32:616–620. 21. Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 2002:359:1004-1010. 22. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363:2022–2031. 23. Grassia G, SEravallec G, Dell’Oroa G et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study J Hypertens 21:1761–1769;2003. 24. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM- Preserved Trial. Lancet 2003; 362:777–781. 25. Berger JP, Akiyama TE and Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends in Pharmacolog Sciens 2005;26:244-51. 26. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR{gamma}-modulating activity. Hypertension 2004; 43:993–1002. 27. Bidani AK Grffin KA Pathophysiology of Hypertensive Renal Damage Implications for Therapy Hypertension. 2004;44:595-601. 28. Navar LG, Harrison-Bernard LM, Nishiyama A et al. Regulation of Intrarenal Angiotensin II in Hypertension Hypertension 2002;39[part 2]:316-322. 29. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60. 30. Brenner BM, Cooper ME, e Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropaty. N Engl J Med 2001;345:861-9. 31. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan onteh developement of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-8. 32. Parving H-H, Persson F, Lewis JB et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358:2433-2446, 2008. 33. Nakao N, Yoshimura A, Morita H, et al: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor in nondiabetic renal disease (COOPERATE): A randomized controlled trial. Lancet 361:117-124, 2002. 34. Pfefer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med 1992;327:669-77. 35. The SOLVD Investigators. The effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91. 36. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients N Engl J Med 2000;342:145-153. 37. Juhan-Vague I, Pyke SDM, Alessi MC et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996;94:2057-63. 38. Tsikouris JP and Cox CD Pharmacologic Blockade of the Renin-Angiotensin System: Vascular Benefits Beyond Commonly Understood Pharmacologic Actions. Pharmacotherapy 2003;23:1141-1152. 39. Jansson JH, Boman K, Nilsson TK. Enalapril-related changes in the fibrinolytic system in survivors of myocardial infarction. Eur J Clin Pharmacol 1993;44:485-8. 40. Pederson OD, Gram J, Jeunemaitre X, et al. Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator- plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction? Coron Artery Dis 1997;8:283-91. 41. Tsikouris JP, Suarez JA, Ziska M, Meyerrose GE. Questioning a class effect: does angiotensin-converting enzyme inhibitor tissue penetration influence markers of myocardial reinfarction risk [abstr]. Pharmacotherapy 2002;22:1326-7. 42. Goodfield N, Newby DE, Ludlam CA, et al. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999;99:2983-5. 43. Fogari R, Zoppi A, Preti P, et al. Differential Effects of ACE-Inhibition and Angiotensin II Antagonism on Fibrinolysis and Insulin Sensitivity in Hypertensive Postmenopausal Women AJH 2001; 14:921–926. 44. Mombouli JV, Vanhoutte PM. Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol 1999;31:61-74. 45. Wolf G, Wenzel U, Burns KD, et al. Angiotensin II activates nuclear transcription factor-kB through AT1 and AT2 receptors. Kidney Int 2002;61:1986-95. 46. Krombach RS, Clair MJ, Hendrick JW, et al. Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns. Cardiovasc Res 1998;38:631-45. 47. Hornig B, Landmesser U, Kohler C, et al. Comparative effect of ACE inhibition and angiotensin II type-1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease. 18 | Editorial Sciens

farmacología cardiovascular 13 | Julio de 2011 Circulation 2001;103:799-805. 48. Rajagpalan S, Kurtz S, Munzel T et al. Angiotensin II mediated hypertension in the rat increase vascular superoxide production via membrene NADH/NADPH oxidase activation. J Clin Invest 1996;97:1916-23. 49. Ridker PM, Hennekens CH, Buring JE. C-reactive protein and other markers of inflammation in the prediction of cardio-vascular disease in women. N Engl J Med 2001;342:836-43. 50. Mendall MA, Strachan DP and Butland BK. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2001;21: 1584-90. 51. Garg S, Narula J, Marelli C et al. Role of Angiotensin Receptor Blockers in the Prevention and Treatment of Arrhytmias. Am J Cardiol 2006;97:921-25. 52. Nattel S, Li D. Ionic remodeling in the heart: pathophysiological significance and new therapeutic opportunities for atrial fibrillation. Circ Res 2000;87:440 -7. 53. Brundel BJJM, Henning RH, Kampinga HH et al. Molecular mechanisms of remodeling in human atrial fibrillation. Cardiovasc Res 2002;54:315–324. 54. Goette A, Bukowska A and Lendeckel U. Non-ion channel blockers as anti-arrhythmic drugs (reversal of structural remodeling) Curr Opinion in Pharmacol 2007, 7:219–224. 55. Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100:376 - 80. 56. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction. Insight from the Studies of Left Ventricular Dysfunction (SOLVD) Trials. Circulation 2003;107:2926 -31. 57. Maggioni AP, Latini R, Carson PE et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT) Am Heart J 2005;149:548-57. 58. Frey N, Katus HA, Olson EN and Hill JA. Hypertrophy of the Heart: A New Therapeutic Target? Circulation 2004;109;1580-1589. 59. Intengan HD and Schiffrin E. Structure and Mechanical Properties of Resistance Arteries in Hypertension Role of Adhesion Molecules and Extracellular Matrix Determinants Hypertension. 2000;36:312-318. 60. Reudelhuber TL, Bernstein KE y Delafontaine P. Is Angiotensin II a Direct Mediator of Left Ventricular Hypertrophy? Time for Another Look. Hypertension 2007;49:1196-1201. 61. Schmieder RE. Mechanisms for the Clinical Benefits of Angiotensin II Receptor Blockers. Am J Hypertens 2005;18:720–730. 62. Kjeldsen SE, Dahlöf B, Devereux RB, et al, for the LIFE Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. JAMA 2002;288:1491–1498. 63. Mathew J, Sleight P, Lonn E, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001;104:1615–1621. 64. Solomon SD, Appelbaum E, Manning WJ, et al., Aliskiren in left ventricular hypertrophy (ALLAY) trial investigators. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119: 530-7. 65. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981–2997. 66. Gaballa MA, Goldman S Ventricular Remodeling in Heart Failure Journal of Cardiac Failure Vol. 8 No. 6 Suppl. 2002. 67. Gheorghiade M, De Luca L and Bonow RO Neurohormonal Inhibition in Heart Failure: Insights from Recent Clinical Trials Am J Cardiol 2005;96[suppl]:3L–9L. 68. Rich S. Endothelin receptor blockers in cardiovascular disease. Circulation 2003;108:2184 –2190. 69. Mann DL, McMurray JJV, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594 –1602. 70. Chung ES, Packer M, Hung Lo K, Fasmanade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-, in patients with moderate-to-severe heart failure: results of the Anti- TNF Therapy Against Congestive Heart failure (ATTACH) trial. Circulation 2003;107:3133–3140. 71. Rademaker MT, Charles CJ, Espiner EA, Nicholls MG, Richards AM, Kosoglou T. Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II. J Cardiovasc Pharmacol 1998;31:116 –125. 72. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian ENalapril SUrvival Study. N Engl J Med 1987; 316:1429 –35. 73. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293–302. 74. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685–91. 75. Granger CB, McMurray JJ, Yusuf S, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function intolerant to angiotensin converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet.2003;362:772–776. 76. McMurray JJ, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008; 1:17-24. 77. Sackner-Bernstein JD and Hart D Neurohormonal Antagonism in Heart Failure: What Is the Optimal Strategy? The Mount Sinai Journal of Medicine 2004;71:115-126. 78. Seneviratne B, Moore GA, West PD. Effect of captopril on functional mitral regurgitation in dilated heart failure: a randomised double blind placebo controlled trial. Br Heart J 1994;72:63– 68. 79. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF, for the ATLAS Study Group. Comparative effects of low-doses and high-doses of the angiotensin converting enzyme inhibitor lisinopril on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312–2318. 80. Nanas JN, Alexopoulos G, Anastasiou-Nana MI, Karidis K, Tirologos A, Zobolos S, Pirgakis V, Anthopoulos L, Sideris D, Stamatelopoulos SF, Moulopoulos SD, for the High Enalapril Dose Study Group Outcome of Patients With Congestive Heart Failure Treated With Standard Versus High Doses of Enalapril: A Multicenter Study J Am Coll Cardiol 2000;36:2090 –5. 81. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582–1587. 82. Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang YT, Benza RL, Gottlieb SO, Kleemann TD, Rosconi F, Vandervoort PM, Cohn JN, for the Val-HeFT Heart Failure Trial Investigators. Valsartan benefits left ventricular structure and function in heart failure: Val- HeFT echocardiographic study. J Am Coll Cardiol 2002;40:970 –975. 83. The ONTARGET Investigators Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. N Engl J Med 2008;358:1547-59. 84. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006; 346:1449–56. 85. Yoshida J, Yamamoto K, Mano T, et al AT1 Receptor Blocker Added to ACE Inhibitor Provides Benefits at Advanced Stage of Hypertensive Diastolic Heart Failure. Hypertension 2004;43;686-691. 86. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM- Preserved trial. Lancet. 2003;362:777-781. 87. Cleland JGF, Tendera M, Adamus J, et al; PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338-2345. Editorial Sciens | 19

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015